RECURSION PHARMACEUTICALS, INC. (RXRX)
RECURSION PHARMACEUTICALS, INC. (RXRX) from its SEC filings: 2025 revenue $74.7 million (+27% vs the year before), net margin -863%, free cash flow -$378.3 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Revenue (2025) | $74.7 million |
| Revenue growth | +27% |
| Net income | -$644.8 million |
| Net margin | -863.4% |
| Free cash flow | -$378.3 million |
| Diluted EPS | $-1.44 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | -60% |
| Cash | $545.7 million |
| Long-term debt | $723,000 |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.